Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
154
resultados
Última actualización
27/09/2024 [07:41:00]
Resultados 50 a 75 de 154
Resumen de: US2024296943A1
System and method for communicating glucose concentration information between devices of a continuous glucose monitoring system is provided. The continuous glucose monitoring system can include a sensor module generates a glucose concentration measurement data and transmits the data to one or more further devices of the continuous glucose monitoring system. The further devices can include a receiver unit and one or more secondary display devices. The receiver unit can be configured to be a stand-alone device of or physically connect to a secondary display device. A user interface can also be provided that provides enhanced functionality for using the continuous glucose monitoring system.
Resumen de: US2024293083A1
Blood glucose states based at least on sensed brain activity data. Blood glucose states may be predicted states using prediction models, and may be real-time or future glucose states. One or more wearable sensors, optionally adapted for use in either single channel or dual channel sensing, can record brain activity signals and communicate brain activity signal data to a remote device.
Resumen de: US2024293085A1
Method, device and system for providing consistent and reliable glucose response information to physiological changes and/or activities is provided to improve glycemic control and health management.
Resumen de: US2024293619A1
A device for monitoring a diabetic patient includes continuous glucose monitoring system that is configured to generate glucose data indicative of the patient's actual glucose level. An continuous subcutaneous insulin infusion pump is configured to inject insulin into the patient and that is configured to generate insulin data regarding when and how much insulin has been injected into the patient. A processor, programmed with a discrete-time reiterative filter, calculates a predicted glucose level corresponding to a predicted glucose level currently expected to be sensed by the continuous glucose monitoring system, based on the insulin data and the glucose data over time and is also programed to generate an alert when the actual glucose level is different from the predicted glucose level by a predetermined amount. An alert generating device is coupled to the processor and is configured to generate an aesthetically-sensible event corresponding to the generation of the alert.
Resumen de: US2024293618A1
Determination of bolus doses and/or bolus doses of insulin and related systems, methods, and devices are disclosed. A method of determining an insulin dose for a meal bolus, correction bolus, and/or basal may include: tracking variations in carbohydrate ratios (CRs) utilizing a Q-learning algorithm, tracking variations in correction factors (CFs) utilizing a nearest-neighbors Q-learning algorithm, and determining a dose for a meal bolus responsive to the tracked CRs and the tracked CFs.
Resumen de: US2024293617A1
Disclosed are techniques to establish initial settings for an automatic insulin delivery device. An adjusted total daily insulin (TDI) factor usable to calculate a TDI dosage may be determined. The adjusted TDI factor may be a TDI per unit of a physical characteristic of the user (e.g., weight) times a reduction factor. The adjusted TDI factor may be compared to a maximum algorithm delivery threshold. Based on the comparison result, the application or algorithm may set a TDI dosage and output a control signal. Blood glucose measurement values may be collected from a sensor over a period of time. A level of glycated hemoglobin of the blood may be determined based on the obtained blood glucose measurement values. In response to the level of glycated hemoglobin, the set TDI dosage may be modified. A subsequent control signal including the modified TDI dosage may be output to actuate delivery of insulin.
Resumen de: US2024293624A1
One or more embodiments of the disclosure relate, generally, to a system to assist with manual dosing of insulin. Such a system may include a glucose sensor system, a reusable insulin dosing detector, and a recommendation system. The reusable insulin dosing detector may be configured to be reversibly connectable to a disposable component that may form part of an insulin manual delivery assembly. The reusable insulin dosing detector may be configured to detect insulin delivery associated with the insulin manual delivery assembly. The recommendation system may be configured to analyze blood glucose data and determine adjustments to insulin therapy settings.
Resumen de: US2024296948A1
Methods and apparatus, including computer program products, are provided for processing analyte data. In some example implementations, a method may include generating glucose sensor data indicative of a host's glucose concentration using a glucose sensor; calculating a glycemic variability index (GVI) value based on the glucose sensor data; and providing output to a user responsive to the calculated glycemic variability index value. The GVI may be a ratio of a length of a line representative of the sensor data and an ideal length of the line. Related systems, methods, and articles of manufacture are also disclosed.
Resumen de: US2024293066A1
Blood glucose states based at least on sensed brain activity data. Blood glucose states may be predicted states using prediction models, and may be real-time or future glucose states. One or more wearable sensors, optionally adapted for use in either single channel or dual channel sensing, can record brain activity signals and communicate brain activity signal data to a remote device.
Resumen de: EP4424234A1
The invention discloses a closed-loop artificial pancreas insulin infusion control system, including: detection module, an infusion module and an electronic module, the detection module, the infusion module and the electronic module all equipped with a control unit, and each control unit is preset with a first algorithm, a second algorithm and a third algorithm correspondingly. When different priority conditions are met, different modules determine the current insulin infusion information. Therefore, the closed-loop artificial pancreas insulin infusion control system can automatically switch control units according to different situations, so as to avoid affecting the user experience and even bringing security risks to users when a module set with the control unit cannot work normally.
Resumen de: AU2022379421A1
Glucose monitoring over phases and corresponding phased information display is described. A multi-phase glucose monitoring program that includes at least a first phase and a second phase is initiated. First glucose data of a user is obtained during the first phase of the multi-phase glucose monitoring program. The output of the first glucose data in a glucose monitoring user interface is prevented during the first phase of the multi-phase glucose monitoring program. Second glucose data of the user is then obtained during a second phase of the multi-phase glucose monitoring program. The second glucose data is output, in real-time, in the glucose monitoring user interface during the second phase of the multi-phase glucose monitoring program.
Resumen de: WO2023070717A1
A closed-loop artificial pancreas drug infusion control system (100), includes an infusion module (110), configured to deliver drugs; a program module (120), comprising an input end (121) and an output end (122), and the input end (121) comprising a plurality of electrically connective regions (121a, 121b) for receiving the current blood glucose level, the program module (120) further preset with a hybrid artificial pancreas algorithm, used for calculating the insulin infusion amount required by the user, the hybrid artificial pancreas algorithm includes a cPID algorithm and/or a cMPC algorithm, where the input of the cPID algorithm is the intermediate value of the MPC algorithm, and the input of the cMPC algorithm is the output value of the PID algorithm; after the output end (122) is electrically connected to the infusion module (110), the program module (120) controls the infusion module (110) to output the drug according to the calculated amount of drug required by the user; and an infusion cannula (130), provided with at least two electrodes (171, 172, 271, 272, 371, 372, 373, 471, 472), the infusion cannula (130) is the drug infusion channel, the electrodes (171, 172, 271, 272, 371, 372, 373, 471, 472) are disposed on the cannula wall (132), when the infusion cannula (130) is installed to the working position, the infusion cannula (130) is connected with the infusion module (110), the drug can then be injected into the body through the infusion cannula (130), and the di
Resumen de: EP4424235A1
The invention discloses a closed-loop artificial pancreas insulin infusion control system, including: a detection module and an infusion module, a detection control unit is set in the detection module, an infusion control unit is set in the infusion module, and at least one calculation control unit is set in the detection module and the infusion module for calculating insulin infusion information and/or further processing of different insulin infusion information. Therefore, the closed-loop artificial pancreas insulin infusion control system can automatically switch the control unit according to different situations to avoid affecting the user experience due to the failure of a module or even bringing safety risks to the user, and to avoid replacing the whole device when only part of the function of some components fails, and to improve the utilization rate of each component of the closed-loop artificial pancreas.
Resumen de: NL2034200B1
The invention relates to a system for regulating the concentration of glucose in the blood of a person, comprising: - a device for selectively supplying at least one and preferably two substances to said person, - at least one and preferably two infusion sets connectable to said device; - at least one sensor for measuring a glucose concentration in the blood of said person; - a controller for controlling said device such that a certain amount of a said substance is supplied per time unit, wherein said controller is arranged to determine a slope of the measured glucose concentration and if said slope exceeds a first threshold value said controller is arranged to control the device to supply a pre-injection amount of said at least one substance, said pre-injection amount being a percentage of a maximum pre-injection amount, wherein said percentage is dependent on the determined slope.
Resumen de: NL2034199B1
The invention relates to a system for regulating the concentration of glucose in the blood of a person, comprising: - a device for selectively supplying insulin and glucagon, - at least two infusion sets, - at least one sensor for measuring a glucose concentration in the blood of said person, and - a controller for controlling said device such that a certain amount of insulin and glucagon is supplied per time unit, wherein said certain amount is chosen in accordance with the measured glucose concentration as prescribed by an insulin injection curve and a glucagon injection curve, wherein said controller is further arranged to determine if glucagon is supplied to said person in a chosen time frame, and wherein the controller is arranged to re-assess and optionally adjust the insulin injection curve based on the determination if glucagon is supplied to said person in said chosen time frame.
Resumen de: NL2034198B1
The invention relates to a system for regulating the concentration of glucose in the blood of a person, comprising: 5 - a device for selectively supplying at least one and preferably two substances, - at least one and preferably two infusion sets connectable to said device for infusing a said substance to said person; - at least one sensor for measuring a glucose concentration in the blood of said person; - a controller for controlling said device such that a certain amount of a said substance is 10 supplied per time unit and thereby infused into the body of the person via said or a respective infusion set, wherein said certain amount is chosen in accordance with the measured glucose concentration, wherein said controller is arranged to determine a slope of the measured glucose concentration, and wherein the time unit per which the certain amount is supplied is dependent on said slope.
Resumen de: EP4397236A2
The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.
Resumen de: EP4397236A2
The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.
Resumen de: AU2023214616A1
The invention refers to an electronic circuit configured to operate an analyte sensor, such as a glucose sensor, the circuit having at least a first and a second electrical connection configured to be connected to a first and a second electrode of the analyte sensor respectively, wherein the electronic circuit has a voltage source and a common potential conductor section electrically provided on a potential of a pole of the voltage source, wherein with the voltage source an electric potential different to the potential of the common potential conductor section can be provided to the first electrical connection; and wherein the second electrical connection is connected to the common potential conductor section through one or more common potential connection paths and wherein none of the common potential connection paths connects the second electrical connection to the common potential conductor section through fewer than three or more series-connected electronic components.
Resumen de: WO2024178261A1
A method, system, and computer readable medium for implementing the Adaptive Bio-Behavioral Control concept, which allows for bi-directional, human-machine co-regulation of metabolic disorders, such as diabetes mellitus. The Adaptive Bio-Behavioral Control concept may encompass, but is not limited thereto, three modules: a) a Physiological Adaptation Module which processes a user's historical data to estimate a personalized model of the user's glucose metabolism and to calculate suggested insulin-dosing parameters; b) a Behavioral Adaptation Module which assists the user's adaptation to the treatment action by determining a plurality of actionable information and risk assessments based on the user's glucose monitoring records; and c) a Replay Module which computes a simulation of effects from hypothetical changes to the user's treatment or behavior based on a personalized model of the user's glucose metabolism.
Resumen de: AU2024205637A1
Systems and methods are described that provide a dynamic reporting functionality that can identify important information and dynamically present a report about the important information that highlights important findings to the user. The described systems and methods are generally described in the field of diabetes management, but are applicable to other medical reports as well. In one implementation, the dynamic reports are based on available data and devices. For example, useless sections of the report, such as those with no populated data, may be removed, minimized in importance, assigned a lower priority, or the like.
Resumen de: US2024285732A1
Compositions of peptide fragments of preproinsulin for the treatment of type 1 diabetes and methods for selecting one or more peptide fragments of preproinsulin suitable for subject-specific immunomodulatory therapy for type 1 diabetes. The one or more peptides may be selected based on an autoimmune phenotype for the subject, which may be characterized by a stimulation assay and/or the based on a genotype for one or more genes related to type 1 diabetes.
Resumen de: US2024285194A1
Methods and devices include automated coaching for management of glucose states by receiving a user's glucose levels using a continuous glucose monitoring (CGM) device, determining a time in range (TIR) value, determining a TIR state, receiving a glucose variability (GV) value, determining a GV state, determining a starting state based on the TIR state and the GV state, determining that the starting state corresponds to a non-ideal state, generating an optimized pathway to reach an ideal state based on one or more account vectors such as addressing self-management behavior including food, activity, and medication use. The optimized pathway may further be based on computer detection and classification of significant events of interest over time.
Resumen de: WO2024175639A1
The invention relates to a system for regulating the concentration of glucose in the blood of a person, comprising: - a device for selectively supplying at least one and preferably two substances to said person, - at least one and preferably two infusion sets connectable to said device; - at least one sensor for measuring a glucose concentration in the blood of said person; - a controller for controlling said device such that a certain amount of a said substance is supplied per time unit, wherein said controller is arranged to determine a slope of the measured glucose concentration and if said slope exceeds a first threshold value said controller is arranged to control the device to supply a pre-injection amount of said at least one substance, said pre-injection amount being a percentage of a maximum pre-injection amount, wherein said percentage is dependent on the determined slope.
Nº publicación: US2024285199A1 29/08/2024
Solicitante:
MEDTRONIC MINIMED INC [US]
Medtronic MiniMed, Inc
Resumen de: US2024285199A1
A continuous glucose monitoring system may utilize externally sourced information regarding the physiological state and ambient environment of its user for externally calibrating sensor glucose measurements. Externally sourced factory calibration information may be utilized, where the information is generated by comparing metrics obtained from the data used to generate the sensor's glucose sensing algorithm to similar data obtained from each batch of sensors to be used with the algorithm in the future. The output sensor glucose value of a glucose sensor may also be estimated by analytically optimizing input sensor signals to accurately correct for changes in sensitivity, run-in time, glucose current dips, and other variable sensor wear effects. Correction actors, fusion algorithms, EIS, and advanced ASICs may be used to implement the foregoing, thereby achieving the goal of improved accuracy and reliability without the need for blood-glucose calibration, and providing a calibration-free, or near calibration-free, sensor.
BOPI
Sede Electrónica
